quinidine

quinidine. Quinidine is a class Ia antiarrhythmic agent and a stereoisomer of the antimalarial compound quinine. It is primarily used to maintain normal sinus rhythm in patients with atrial fibrillation and to prevent life-threatening ventricular arrhythmias like ventricular tachycardia. The drug works by blocking cardiac sodium and potassium channels, thereby prolonging the cardiac action potential and increasing the refractory period of the heart muscle. Its use has declined with the advent of newer agents and due to a significant side effect profile, but it remains an important option in specific clinical scenarios.

Medical uses

Quinidine is indicated for the prophylaxis and treatment of various cardiac arrhythmias, including the maintenance of normal sinus rhythm after conversion from atrial fibrillation or atrial flutter. It is also used in the management of paroxysmal supraventricular tachycardia and for the prevention of ventricular tachycardia or ventricular fibrillation, particularly in conditions like Brugada syndrome. Historically, it was a mainstay for treating malaria caused by Plasmodium falciparum, especially chloroquine-resistant strains, though this use has been largely supplanted by artemisinin-based combination therapies. The drug is often administered in conjunction with agents that slow atrioventricular nodal conduction, such as digoxin or a beta blocker, to mitigate its vagolytic effects which can increase ventricular rate.

Adverse effects

The use of quinidine is associated with a wide range of adverse effects, some of which are severe. A well-known and potentially fatal reaction is quinidine syncope, which involves torsades de pointes, a specific form of polymorphic ventricular tachycardia precipitated by QT interval prolongation. Common gastrointestinal disturbances include cinchonism, a syndrome characterized by nausea, vomiting, diarrhea, tinnitus, and headache. Hematologic effects can be serious, including thrombocytopenia and immune-mediated hemolytic anemia. Other significant risks include profound hypotension, exacerbation of heart failure, and drug interactions that can lead to toxicity, particularly with agents metabolized by the cytochrome P450 system, such as warfarin and digoxin. Hypersensitivity reactions, including rash and fever, have also been reported.

Pharmacology

Quinidine exerts its antiarrhythmic effects primarily by blocking the fast inward sodium current (I_Na) during phase 0 of the cardiac action potential, which slows conduction in the His-Purkinje system and ventricular muscle. It also blocks several potassium repolarizing currents, notably the rapid component of the delayed rectifier potassium current (I_Kr), leading to action potential prolongation and an increased effective refractory period. Pharmacokinetically, it is well-absorbed from the gastrointestinal tract, undergoes significant metabolism in the liver via the CYP3A4 and CYP2D6 isoenzymes, and has an active metabolite, 3-hydroxyquinidine. Its elimination half-life is approximately 6 to 8 hours, and it exhibits anticholinergic (vagolytic) properties which contribute to its clinical effects and side effects.

History

The history of quinidine is closely tied to that of its stereoisomer, quinine, which was isolated from the bark of the Cinchona tree native to South America. While quinine's antimalarial properties were recognized for centuries, the cardiac effects of cinchona alkaloids were noted in the 18th century. Quinidine was first isolated and identified by the Dutch pharmacists Pieter van der Burg and Abraham van der Burg in 1848. Its specific antiarrhythmic properties were systematically described by the German physician Walter von Frey in 1918. It became a cornerstone of arrhythmia management in the mid-20th century, with its use championed by cardiologists like Dennis Krikler. Its role diminished following the Cardiac Arrhythmia Suppression Trial (CAST), which raised concerns about the safety of class I antiarrhythmics, and with the development of drugs like amiodarone and dofetilide.

Society and culture

Quinidine has been available under various brand names, including Quinidex and Cardioquin, and is on the World Health Organization's List of Essential Medicines. Its production and supply have occasionally been affected by shortages of the cinchona bark. In popular culture, references to "quinine" often encompass its isomers, reflecting its historical importance. The drug's propensity to cause serious arrhythmias has made it a classic teaching example in pharmacology and cardiology for drug-induced long QT syndrome. Legal and regulatory scrutiny increased post-CAST, influencing prescribing guidelines from bodies like the American Heart Association and the European Society of Cardiology. Its use today is often guided by genetic testing for variants in genes like CYP2D6 to predict metabolic status and risk of toxicity.

Category:Antiarrhythmic agents Category:World Health Organization essential medicines